Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
177 Results for "
hematologic malignancy
" in MedChemExpress (MCE) Product Catalog:
Products (177)
177 Results for "hematologic malignancy" in MCE Product Catalog:
Cat. No.: HY-P99475
CAS No.: 2460539-60-8
Synonyms: MSB-2311
Target:
Research Areas:
Synonyms: OKI-179
Bocodepsin (OKI-179) is an orally active and selective HDAC inhibitor, with antitumor activity. Bocodepsin can be used for suppression on solid tumor and hematologic malignancies .
Cat. No.: HY-P990077
CAS No.: 1036730-42-3
Synonyms: CT-011; MDV9300
Target:
Research Areas:
Cat. No.: HY-P11097
CAS No.: 3056822-31-9
Target:
Research Areas:
Cat. No.: HY-10984A
CAS No.: 202271-89-4
Synonyms: (S)-CC-4047
Target:
Research Areas:
(S)-Pomalidomide ((S)-CC-4047) is an angiogenesis-inhibiting drug with growth-inhibitory activity against B-cell tumors. (S)-Pomalidomide can induce complete tumor regression in BurKitt lymphoma cells. (S)-Pomalidomide serves as an immunomodulator with potential applications in inhibiting hematological malignancies .
Target:
Research Areas:
Immunoproteasome inhibitor 1 is a potent, reversible, time-independent immunoproteasome and proteasome inhibitor (Kis of 1.18, 0.27, 1.91 μM in β5c, β1i, β5i submits, respectively). Immunoproteasome inhibitor 1 can be used for the research of certain neoplastic diseases .
Cat. No.: HY-179105
CAS No.: 2487649-59-0
Target:
Research Areas:
Axl-IN-20 (Compound w11) is a selective, orally active AXL inhibitor, with an IC50 of 5 nM. Axl-IN-20 has antitumor activity against hematological malignancies .
Cat. No.: HY-175036
YTHu78 is a KDM5B PROTAC degrader. YTHu78 induces KDM5B degradation via the ubiquitin-proteasome system and CRBN E3 ligase, and triggers lytic apoptosis in hematologic malignant cells. YTHu78 can be used in studies related to hematologic malignancies .
Cat. No.: HY-170434
CAS No.: 3106363-91-8
Target:
Research Areas:
Bfl-1-IN-6 is an orally active BFL1 inhibitor with an IC50 of 19 nM. Bfl-1-IN-6 selectively binds covalently to BFL1, stabilizes the protein and displaces BIM from BFL1, thereby inducing apoptosis activity. Bfl-1-IN-6 stabilizes BFL1 protein, activates cleaved caspase 3, and exhibits antitumor activity in mouse models. Bfl-1-IN-6 can be used for the research of hematological malignancies .
Synonyms: CPX-POM
Target:
Research Areas:
Fosciclopirox (CPX-POM) suppresses growth of urothelial cancer by targeting the γ-secretase complex. Fosciclopirox selectively delivers the active metabolite, Ciclopirox (CPX), to the entire urinary tract. Ciclopirox has anticancer activity in a number of solid and hematologic malignancies .
Cat. No.: HY-15901A
CAS No.: 1469925-36-7
LGB321 monohydrochloride is a potent, selective, orally active and ATP competitive inhibitor of all three PIM kinases. LGB321 monohydrochloride inhibits proliferation, mTOR-C1 signaling and phosphorylation of BAD in a number of cell lines derived from diverse hematologic malignancies. LGB321 monohydrochloride can be used for the research of hematologic malignancies .
Cat. No.: HY-114255
CAS No.: 261929-52-6
Synonyms: alpha-TEA
Alpha-tocopheryloxyacetic acid (alpha-TEA) is an inducer of cancer cell apoptosis pathway. Alpha-tocopheryloxyacetic acid is promising for research of solid and hematological malignancies .
Cat. No.: HY-159707
CAS No.: 2309309-69-9
Target:
Research Areas:
MCL1020 is a CHK1 inhibitor with an IC50 of 1.61 μM. MCL1020 properly occupies the ATP pocket by interacting with a diverse range of the sites of CHK1 kinase. MCL1020 can be used for the study of hematologic malignancies .
Cat. No.: HY-100885A
CAS No.: 1562406-27-2
Synonyms: (S)-NUC-1031; Fosgemcitabine palabenamide
(S)-Acelarin ((S)-NUC-1031) is an anti-cancer agent. (S)-Acelarin inhibits the growth of various cancer cells. (S)-Acelarin can be used for the study of solid tumors (e.g., pancreatic cancer, BTC, ovarian cancer) and hematological malignancies .
Cat. No.: HY-178468
CAS No.: 3053592-61-0
PARP1-IN-47 (Compound 35) is a highly selective PARP1 inhibitor (IC50 <100 nM). PARP1-IN-47 blocks poly(ADP-ribosyl)ation and disrupts DNA damage repair pathways to induce tumor cell apoptosis. PARP1-IN-47 is promising for research of solid tumors and hematological malignancies .
Cat. No.: HY-159808
CAS No.: 875165-39-2
Target:
Research Areas:
TCL1 is a selective non-covalent inhibitor targeting the Pru domain of the Rpn-13 subunit in the 19S regulatory particle (19S RP) of the proteasome with an IC50 value of approximately 26 μM. TCL1 interferes with the recognition and transport of ubiquitinated proteins by Rpn-13, inhibits the degradation of proteins by the proteasome, and thus affects the balance of intracellular protein metabolism. TCL1 is promising for research of hematological malignancies .
Cat. No.: HY-P991151
CAS No.: 2923499-76-5
Synonyms: LBL-024
Target:
Research Areas:
Opamtistomig is a humanized immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody targeting human programmed death ligand 1 (PD-L1), CD274 and tumor necrosis factor receptor superfamily member 9 (TNFRSF9). Opamtistomig is promising for research of various solid tumors and hematological malignancies .
Cat. No.: HY-P991638
Target:
Research Areas:
Cat. No.: HY-158618
CAS No.: 958226-81-8
Target:
Research Areas:
Aurora kinase inhibitor-14 (Compound 79) is an orally active and highly selective inhibitor of Aurora kinases with IC50 values of 0.5 nM and 1.2 nM for Aurora A and Aurora B, respectively. Aurora kinase inhibitor-14 binds to the ATP-binding site of Aurora kinases to block chromosome segregation during mitosis and induce apoptosis in tumor cells. Aurora kinase inhibitor-14 is promising for research of various solid tumors and hematological malignancies, such as non-small cell lung cancer, breast cancer, and acute myeloid leukemia .
Cat. No.: HY-175261
Target:
Research Areas:
DHI1 is an anti-leukemia agent with high selectivity for Jurkat (IC50 = 21.83 μM) and HL-60 (IC50 = 19.14 μM) leukemia cells and has low toxicity to non-cancerous cells. DHI1 can induce G2/M phase cell arrest in Jurkat and HL-60 leukemia cells, as well as S phase arrest in HL-60 cells, and has significant effects on cell cycle signaling molecules Wee1, cyclin B1, cdc2 on Tyr15, and Chk1. DHI1 inhibits the migration and invasion of Jurkat and HL-60 cells by disrupting cytoskeletal actin filaments. DHI1 can be used to study hematological malignancies .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
